Travere Therapeutics (TVTX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Travere Therapeutics Revenue Highlights

Latest Revenue (Y)

$490.73M

Latest Revenue (Q)

$164.86M

Main Segment (Y)

Product

Travere Therapeutics Revenue by Period

Travere Therapeutics Revenue by Year

Date	Revenue	Change
2025-12-31	$490.73M	110.45%
2024-12-31	$233.18M	60.55%
2023-12-31	$145.24M	32.69%
2022-12-31	$109.46M	-16.97%
2021-12-31	$131.84M	-33.52%
2020-12-31	$198.32M	13.11%
2019-12-31	$175.34M	6.75%
2018-12-31	$164.25M	6.01%
2017-12-31	$154.94M	15.98%
2016-12-31	$133.59M	33.74%
2015-12-31	$99.89M	254.19%
2014-12-31	$28.20M	100.00%
2013-12-31	-	100.00%
2012-12-31	-	100.00%
2012-02-29	-	100.00%
2011-02-28	-	100.00%
2010-02-28	-	100.00%
2009-02-28	-	-

Travere Therapeutics generated $490.73M in revenue during NA 2025, up 110.45% compared to the previous quarter, and up 247.44% compared to the same period a year ago.

Travere Therapeutics Revenue by Quarter

Date	Revenue	Change
2025-09-30	$164.86M	44.05%
2025-06-30	$114.45M	40.03%
2025-03-31	$81.73M	9.29%
2024-12-31	$74.79M	18.90%
2024-09-30	$62.90M	16.23%
2024-06-30	$54.12M	30.80%
2024-03-31	$41.37M	-8.18%
2023-12-31	$45.06M	21.47%
2023-09-30	$37.09M	-37.86%
2023-06-30	$59.70M	4.74%
2023-03-31	$56.99M	2.01%
2022-12-31	$55.87M	4.43%
2022-09-30	$53.50M	-1.24%
2022-06-30	$54.17M	11.71%
2022-03-31	$48.49M	-15.31%
2021-12-31	$57.25M	-16.08%
2021-09-30	$68.22M	24.90%
2021-06-30	$54.62M	15.21%
2021-03-31	$47.41M	-7.01%
2020-12-31	$50.98M	-0.31%
2020-09-30	$51.14M	5.59%
2020-06-30	$48.43M	1.38%
2020-03-31	$47.77M	2.32%
2019-12-31	$46.69M	5.21%
2019-09-30	$44.37M	-0.75%
2019-06-30	$44.71M	12.98%
2019-03-31	$39.57M	-9.60%
2018-12-31	$43.77M	7.53%
2018-09-30	$40.71M	-1.53%
2018-06-30	$41.34M	7.56%
2018-03-31	$38.43M	-8.88%
2017-12-31	$42.18M	4.55%
2017-09-30	$40.34M	3.97%
2017-06-30	$38.80M	15.41%
2017-03-31	$33.62M	-9.93%
2016-12-31	$37.33M	9.96%
2016-09-30	$33.95M	1.90%
2016-06-30	$33.31M	14.83%
2016-03-31	$29.01M	-4.73%
2015-12-31	$30.45M	8.72%
2015-09-30	$28.00M	16.36%
2015-06-30	$24.07M	38.55%
2015-03-31	$17.37M	23.34%
2014-12-31	$14.08M	68.71%
2014-09-30	$8.35M	45.40%
2014-06-30	$5.74M	20479.69%
2014-03-31	$27.90K	100.00%
2013-12-31	-	100.00%
2013-09-30	-	100.00%
2013-06-30	-	100.00%
2013-03-31	-	100.00%
2012-11-30	-	100.00%
2012-08-31	-	100.00%
2012-05-31	-	100.00%
2012-02-29	-	100.00%
2011-11-30	-	100.00%
2011-08-31	-	100.00%
2011-05-31	-	100.00%
2011-02-28	-	100.00%
2010-11-30	-	100.00%
2010-08-31	-	100.00%
2010-05-31	-	-

Travere Therapeutics generated $164.86M in revenue during Q3 2025, up 44.05% compared to the previous quarter, and up 304.64% compared to the same period a year ago.

Travere Therapeutics Revenue Breakdown

Travere Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Product	$410.46M	$200.53M	$210.78M	-	-
License	$80.27M	$6.47M	$17.70M	-	-
Royalty	-	$600.00K	-	-	-
Active Pharmaceutical Ingredient	-	-	$3.30M	-	-
Bile Acid Products	-	-	-	$102.56M	$95.65M
Tiopronin Products	-	-	-	$97.97M	$115.12M

Travere Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (83.64%), and License (16.36%).

Quarterly Revenue by Product

Product/Service	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
License	$3.08M	$51.71M	$19.61M	$5.87M	$1.24M	$1.90M	$1.94M	$1.39M	$14.54M	$3.16M	$2.67M	-	-	-	-	-	-	-	-	-
Product	$221.45M	$113.15M	$75.86M	$61.00M	$52.18M	$39.98M	$57.01M	$50.28M	$52.34M	$50.79M	$50.95M	$46.44M	$54.58M	$54.17M	-	-	-	-	-	-
Royalty	-	-	$600.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Active Pharmaceutical Ingredient	-	-	-	-	-	-	-	-	-	$3.30M	-	-	-	-	-	-	-	-	-	-
Bile Acid Products	-	-	-	-	-	-	-	-	-	-	$27.50M	$26.11M	$26.53M	$25.42M	$25.53M	$25.07M	$24.35M	$24.97M	$21.96M	-
Tiopronin Products	-	-	-	-	-	-	-	-	-	-	$26.05M	$21.17M	$25.82M	$25.37M	$25.42M	$21.37M	$29.82M	$29.64M	$25.44M	-

Travere Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Product (98.63%), and License (1.37%).

Travere Therapeutics Revenue Breakdown by Country

Quarterly Revenue by Country

Country	Sep 25	Mar 22
Non-US	$42.40M	-
FRANCE	-	$8.00M

Travere Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 25: Non-US (100.00%).

Travere Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
AAPG	ASCENTAGE PHARMA GROUP	$980.65M	$141.22K
RARE	Ultragenyx Pharmaceutical	$673.00M	$159.93M
TVTX	Travere Therapeutics	$490.73M	$164.86M
TARS	Tarsus Pharmaceuticals	$451.36M	$118.70M
LEGN	Legend Biotech	$285.14M	$93.99M
XENE	Xenon Pharmaceuticals	$7.50M	-
CGON	CG Oncology	$4.04M	$1.67M
IRON	Disc Medicine	-	$7.91M
APGE	Apogee Therapeutics	-	-
CNTA	Centessa Pharmaceuticals	-	-
CELC	Celcuity	-	$154.00K

TVTX Revenue FAQ

What is Travere Therapeutics’s yearly revenue?

Travere Therapeutics's yearly revenue for 2025 was $490.73M, representing an increase of 110.45% compared to 2024. The company's yearly revenue for 2024 was $233.18M, representing an increase of 60.55% compared to 2023. TVTX's yearly revenue for 2023 was $145.24M, representing an increase of 32.69% compared to 2022.

What is Travere Therapeutics’s quarterly revenue?

Travere Therapeutics's quarterly revenue for Q3 2025 was $164.86M, a 44.05% increase from the previous quarter (Q2 2025), and a 162.11% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $114.45M, a 40.03% increase from the previous quarter (Q1 2025), and a 111.49% increase year-over-year (Q2 2024). TVTX's quarterly revenue for Q1 2025 was $81.73M, a 9.29% increase from the previous quarter (Q4 2024), and a 97.54% increase year-over-year (Q1 2024).

What is Travere Therapeutics’s revenue growth rate?

Travere Therapeutics's revenue growth rate for the last 3 years (2023-2025) was 237.88%, and for the last 5 years (2021-2025) was 272.23%.

What are Travere Therapeutics’s revenue streams?

Travere Therapeutics's revenue streams in c 25 are Product, and License. Product generated $410.46M in revenue, accounting 83.64% of the company's total revenue, up 104.69% year-over-year. License generated $80.27M in revenue, accounting 16.36% of the company's total revenue, up 1141.00% year-over-year.

What is Travere Therapeutics’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Travere Therapeutics was Product. This segment made a revenue of $410.46M, representing 83.64% of the company's total revenue.